Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform
Rhea-AI Summary
Abbott (NYSE: ABT) and Flatiron Health integrated Abbott's Precision Oncology portfolio into Flatiron's OncoEMR on March 30, 2026. The integration lets clinicians order Abbott tests and receive results inside the OncoEMR workflow, expanding access across Flatiron's network of 1,600+ community cancer centers and 4,700 providers.
This single, unified experience covers Oncotype DX Breast Recurrence Score®, OncoExTra®, Oncodetect®, and Riskguard®, aiming to reduce administrative burden and accelerate informed treatment decisions in community oncology settings.
Positive
- Network reach: expands access to Abbott tests across >1,600 community cancer centers
- Provider access: integrates with workflows used by 4,700 providers in Flatiron's North America network
- Portfolio unification: enables ordering and results for multiple tests (Oncotype DX, OncoExTra, Oncodetect, Riskguard) within OncoEMR
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
ABT was down 0.55% pre-news, while key device peers like BSX, SYK, MDT, EW, and SNN also showed same-day declines (e.g., EW -3.01%, SYK -1.57%). Momentum data flags only BSX in the scanner, so the move appears more stock-specific than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Earnings call notice | Neutral | -0.3% | Announcement of timing and access details for Q1 2026 earnings call. |
| Mar 24 | Awareness campaign | Positive | -0.8% | Cologuard-focused campaign with celebrity partners to boost screening uptake. |
| Mar 23 | Acquisition completion | Positive | -0.6% | Closing of Exact Sciences acquisition and addition of oncology portfolio. |
| Mar 20 | Acquisition update | Positive | -1.6% | Pre-close update on Exact deal, including projected 2026 sales and EPS impact. |
| Mar 12 | Clinical trial data | Positive | -1.9% | FreeDM2 trial showed improved HbA1c and time-in-range with Libre CGM. |
Recent positive clinical, acquisition, and campaign news items have often been followed by short-term share price declines, indicating a pattern of negative reactions to ostensibly favorable updates.
Over the past month, Abbott has focused on expanding its presence in cancer screening and metabolic disease management. It completed the Exact Sciences acquisition on Mar 23, 2026, adding Cologuard and multiple precision oncology tests, following earlier guidance that the deal could add ~$3 billion of 2026 sales but dilute EPS. A FreeStyle Libre study showed improved glucose control, and a Cologuard awareness campaign launched on Mar 24. Despite these developments, shares saw negative 24-hour reactions, similar to the mild pullback around today’s oncology integration news.
Regulatory & Risk Context
Abbott has an effective Form S-3ASR shelf prospectus dated February 23, 2026, allowing it to offer debt securities, common shares, preferred shares, depositary shares, warrants, purchase contracts, and units from time to time. The filing notes 1,737,682,887 common shares outstanding and 2,400,000,000 authorized common shares as of January 31, 2026, and has already been used in recent 424B3 and 424B5 offerings.
Market Pulse Summary
This announcement expands digital access to Abbott’s Precision Oncology portfolio by embedding test ordering and results into Flatiron’s OncoEMR® for more than 1,600 community cancer centers and 4,700 providers. It follows the Exact Sciences acquisition, which added core cancer screening assets. Together, these steps underscore a strategy to integrate diagnostics more tightly into oncology workflows. Investors may watch adoption across community practices, incremental volume trends in key tests, and how this integration supports the broader oncology growth narrative.
Key Terms
precision oncology medical
electronic medical record (emr) technical
AI-generated analysis. Not financial advice.
- Broadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's
North America network, helping accelerate informed treatment decisions - Allows oncologists to order tests and view results directly in the clinical workflow
ABBOTT PARK, Ill. and
Through this integration, oncology providers can now digitally order Abbott tests – individually or in combination – and receive status updates and results directly within their existing OncoEMR clinical workflow. Available Abbott tests include the Oncotype DX Breast Recurrence Score®, OncoExTra®, Oncodetect®, and Riskguard® tests, enabling clinicians to access the comprehensive portfolio through a single, unified experience. This approach supports more informed treatment decisions across multiple stages of cancer care while helping reduce administrative burden and keeping the focus on patient care.
The integration expands access to Abbott's Precision Oncology tests across Flatiron's national network of more than 1,600 community cancer care centers, where 4,700 providers deliver care and where most cancer care in the
"We're focused on making it easier for clinicians to access the right information at the right moment of care," said Quincy Weatherspoon, VP and GM of Point of Care Solutions, Flatiron Health. "By integrating Abbott's Precision Oncology portfolio directly into OncoEMR, we're reducing friction in the workflow and helping providers move faster – from test ordering to treatment decisions. This is what it looks like to bring more connected, data-driven care to the point of care."
"For community oncology practices, where most cancer care is delivered, this removes a key barrier to accessing our portfolio at the point of care, helping accelerate treatment decisions and enabling more informed, personalized patient care," said Brian Baranick, vice president, Precision Oncology, Abbott.
About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
View original content:https://www.prnewswire.com/news-releases/abbott-expands-access-to-precision-oncology-portfolio-through-integration-with-flatirons-oncoemr-platform-302728101.html
SOURCE Abbott
FAQ
What did Abbott (ABT) announce on March 30, 2026 about OncoEMR integration?
How many centers and providers will have access to Abbott tests through the ABT and Flatiron deal?
Which Abbott Precision Oncology tests are available in OncoEMR for ABT investors and clinicians?
How will the OncoEMR integration affect clinician workflow for Abbott tests (ABT)?
Does the ABT and Flatiron integration change where Abbott Precision Oncology tests are performed?
